AR and neoplasm: As PIK3CA mutations are found to be more frequent in TNBC-expressing androgen receptors (40% of AR+ tumours vs. 4% in AR- TNBC), different trials have also evaluated the safety and efficacy of enzalutamide in association with the PI3K inhibitors alpelisib or taselisib [66].